• Hidetomo Murakami, Tomotaka Shiraishi, Tadashi Umehara, Shusaku Omoto, and Yasuyuki Iguchi.
• Department of Neurology, the Jikei University School of Medicine, Japan.
• Intern. Med. 2023 Jan 1; 62 (1): 334233-42.

AbstractParkinson's disease (PD) is a neurodegenerative disease manifesting with motor and non-motor symptoms. Current treatment mainly relies on medication as a symptomatic therapy modulating neurotransmitters. Dopamine replacement therapy has been established, and levodopa is the gold standard for treatment of PD. However, the emergence of motor complications, such as a wearing-off phenomenon, is a clinical problem. Both primary symptoms and motor complications have been targets for the development of treatments for PD. Recent progression in the management of motor complications is supported by newly developed agents and advances in device and formulation technology to deliver drugs continuously. Elucidation of the pathophysiology of PD and the development of disease-modifying therapy that affects the underlying fundamental pathophysiology of the disease are also progressing. In this review, we introduce current knowledge on developments concerning medications for patients with PD.

12 keywords...

hide…